Skip to content

Study · Animal study (in vivo) · mouse · 2014

5 results

Thymosin β4 reduces IL-17-producing cells and IL-17 expression, and protects lungs from damage in bleomycin-treated mice.

Conte E, Iemmolo M, Fagone E, Gili E, Fruciano M, Genovese T, Esposito E, Cuzzocrea S, Vancheri C

Immunobiology14 Feb 2014Cited by 18 (Europe PMC)

PMID24613476 (opens in a new tab)DOI10.1016/j.imbio.2014.02.001 (opens in a new tab)PepBankPUB-24613476
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In bleomycin-treated CD-1 mice, Tβ4 significantly reduced leukocytes in bronchoalveolar lavage fluid.

    In plain wordsIn mice with bleomycin lung damage, Tβ4 lowered white blood cells in lung fluid.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    DecreaseLeukocytes in BALF
    Study

    mousen: not reported in source

    Bleomycin-induced lung damage in CD-1 mice
    Comparator
    Bleomycin without Tβ4
    Outcome group
    Inflammation markers · Respiratory
    Studied dose
    6 mg/kg · intraperitoneal · 3 doses, tissue collected one week laterAs given in this study (mouse).

    Source sentences

    Summary
    As expected, bleomycin-induced inflammation and lung damage were substantially reduced by Tβ4 treatment in CD-1 mice, as shown by the significant reduction of (i) leukocytes in BALF, (ii) histological evidence of the lung damage, and (iii) total collagen content in the lung.
    1 context sentence
    Summary · context
    Male CD-1 mice were treated with bleomycin (1mg/kg) in the absence or the presence of Tβ4 (6mg/kg delivered intra-peritoneally on the day of bleomycin treatment and for 2 additional doses).
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In bleomycin-treated CD-1 mice, Tβ4 significantly reduced histological evidence of lung damage.

    In plain wordsIn mice with bleomycin lung damage, Tβ4 reduced signs of lung damage under the microscope.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    DecreaseHistological lung damage
    Study

    mousen: not reported in source

    Bleomycin-induced lung damage in CD-1 mice
    Comparator
    Bleomycin without Tβ4
    Outcome group
    Inflammation markers · Respiratory
    Studied dose
    6 mg/kg · intraperitoneal · 3 doses, tissue collected one week laterAs given in this study (mouse).

    Source sentences

    Summary
    As expected, bleomycin-induced inflammation and lung damage were substantially reduced by Tβ4 treatment in CD-1 mice, as shown by the significant reduction of (i) leukocytes in BALF, (ii) histological evidence of the lung damage, and (iii) total collagen content in the lung.
    1 context sentence
    Summary · context
    Male CD-1 mice were treated with bleomycin (1mg/kg) in the absence or the presence of Tβ4 (6mg/kg delivered intra-peritoneally on the day of bleomycin treatment and for 2 additional doses).
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In bleomycin-treated CD-1 mice, Tβ4 significantly reduced total collagen content in the lung.

    In plain wordsIn mice with bleomycin lung damage, Tβ4 lowered collagen in the lung.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    DecreaseTotal lung collagen content
    Study

    mousen: not reported in source

    Bleomycin-induced lung damage in CD-1 mice
    Comparator
    Bleomycin without Tβ4
    Outcome group
    Inflammation markers · Respiratory
    Studied dose
    6 mg/kg · intraperitoneal · 3 doses, tissue collected one week laterAs given in this study (mouse).

    Source sentences

    Summary
    As expected, bleomycin-induced inflammation and lung damage were substantially reduced by Tβ4 treatment in CD-1 mice, as shown by the significant reduction of (i) leukocytes in BALF, (ii) histological evidence of the lung damage, and (iii) total collagen content in the lung.
    1 context sentence
    Summary · context
    Male CD-1 mice were treated with bleomycin (1mg/kg) in the absence or the presence of Tβ4 (6mg/kg delivered intra-peritoneally on the day of bleomycin treatment and for 2 additional doses).
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In bleomycin-treated CD-1 mice, Tβ4 significantly blocked the bleomycin-induced increase in IL17-producing cells in the blood.

    In plain wordsIn mice with bleomycin lung damage, Tβ4 blocked the rise in IL17-producing blood cells.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    DecreaseIL17-producing cells in blood
    Study

    mousen: not reported in source

    Bleomycin-induced lung damage in CD-1 mice
    Comparator
    Bleomycin without Tβ4
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    6 mg/kg · intraperitoneal · 3 doses, tissue collected one week laterAs given in this study (mouse).

    Source sentences

    Summary
    Importantly, the bleomycin-induced increase in the number of IL17-producing cells in the blood was significantly blocked by Tβ4.
    1 context sentence
    Summary · context
    Male CD-1 mice were treated with bleomycin (1mg/kg) in the absence or the presence of Tβ4 (6mg/kg delivered intra-peritoneally on the day of bleomycin treatment and for 2 additional doses).
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In bleomycin-treated CD-1 mice, Tβ4 substantially inhibited bleomycin-induced IL-17 over-expression in lung tissue.

    In plain wordsIn mice with bleomycin lung damage, Tβ4 reduced the rise in IL-17 in lung tissue.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    DecreaseIL-17 expression in lung tissue
    Study

    mousen: not reported in source

    Bleomycin-induced lung damage in CD-1 mice
    Comparator
    Bleomycin without Tβ4
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    6 mg/kg · intraperitoneal · 3 doses, tissue collected one week laterAs given in this study (mouse).

    Source sentences

    Summary
    Accordingly, IHC and RT-PCR results demonstrated that Tβ4 substantially inhibited bleomycin-induced IL-17 over-expression in the lung tissue.
    1 context sentence
    Summary · context
    Male CD-1 mice were treated with bleomycin (1mg/kg) in the absence or the presence of Tβ4 (6mg/kg delivered intra-peritoneally on the day of bleomycin treatment and for 2 additional doses).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 01:52 UTC

    Study results updated

  2. Version 1

    12 Oct 2026, 18:17 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.